Clinical Trial Search

Primary: Progression-Free Survival in Participants With PD-L1 Expression >= 5% — 4.21; 5.88 Months — p=0.2511

Primary: Percentage of Successful Task Completions — 100; 100; 100; 100 percentage of tasks

Primary: Tolerability of AC 170 0.24% at Visit 1 (Day 1) — 0.87; 0.50; 0.64; 0.42 units on a scale

Primary: Number of Participants With Demonstrated Improvement From Baseline on the Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall — 20; 23 Participants

Primary: Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at…

Primary: DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 — -2.20; -3.28 units on a scale…

Primary: Event Free Survival (EFS) — 0.6255; 0.5874 Probability

Primary: Percentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 52 — 48.4; 61.4 Percentage of par. — p=0.0006

Primary: Difference in Pain Level at Time of Cervical Dilation as Measured by a Visual Analog Scale — 68; 65 units on a scale

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -1.13; -1.12; -1.19 percentage of HbA1c — p=<0.001

Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 1.0; -54.9 percent change — p=<0.001

Primary: Haemostatic Effect During Surgery Evaluated by the Four-point Response Scale (Excellent, Good, Moderate, Poor) — 10; 3; 0; 0 Haemostatic responses

Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change

Primary: Change From Baseline in Hemoglobin A1C at Week 26 — -0.78; -0.86; -0.09 Percent — p=<0.001

Primary: H01: All Cause Mortality — 244; 218 participants — p=0.12